 Meridian Bioscience Inc NASDAQ: VIVO posted Q4 sales of 76.2 million, up 19 YY, beating the consensus of 68.40 million. Diagnostics segment net revenues increased 15 YY to 34.3 million, led by a 22 increase in molecular products sales, and non-molecular assay products sales increased 14, despite the impact of the LeadCare product recall. 